Gland Pharma Ltd.

NSE: GLAND | BSE: 543245

Strong Performer, Getting Expensive

In 1 Starfolio Basket

Download real time

2232.30 -44.70 (-1.96%)

41.86% Gain from 52W Low

263.2K

NSE+BSE Volume

NSE 03 Jun, 2026 3:31 PM (IST)

Gland Pharma Ltd. share price target

Gland Pharma Ltd. has an average share price target of 2288.33. The consensus estimate represents an upside of 2.51% from the last price of 2232.30. View 9 reports from 3 analysts offering long-term price targets for Gland Pharma Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	04 Jun 2026	Gland Pharma	Consensus Share Price Target	2232.30	2189.57	-	-1.91	buy	pdf Detailed Estimates
	22 May 2026	Gland Pharma	ICICI Direct Target	2232.30	2645.00	2334.00 (-4.36%)	18.49	Buy	pdf post cache		Broker Report Gland Pharma ICICI Direct About the stock: Gland Pharma is one of the largest generic injectable-focused Along with its partners, Gland owns 1,748 products registrations globally of which ~490 in US, Europe, Canada, Australia, and New Zealand, ~73 in... pdf Copy Link Share on Share on Share on Share on Alert
	29 Jan 2026	Gland Pharma	Axis Direct Reco	2232.30	2170.00	1800.10 (24.01%)	Target met	Buy	pdf post cache		Broker Report Result Update:Gland Pharma Axis Direct We maintain our BUY rating on the stock. pdf Copy Link Share on Share on Share on Share on Alert
	29 Jan 2026	Gland Pharma	ICICI Direct Target	2232.30	2275.00	1800.10 (24.01%)	Target met	Buy	pdf post cache		Broker Report Gland Pharma ICICI Direct About the stock: Gland Pharma is one of the largest generic injectable-focused Along with its partners, Gland owns 1,748 products registrations globally of which ~490 in US, Europe, Canada, Australia, and New Zealand, ~73 in... pdf Copy Link Share on Share on Share on Share on Alert
	28 Jan 2026	Gland Pharma	Motilal Oswal Target	2232.30	2050.00	1689.70 (32.11%)	Target met	Buy	pdf post cache		Broker Report Cenexi break-even/US uptrend drives earnings beat Motilal Oswal Gland Pharma (GLAND) delivered better-than-expected 3QFY26 financial performance with a 6%/14%/19% beat on revenue/EBITDA/PAT. pdf Copy Link Share on Share on Share on Share on Alert
	04 Nov 2025	Gland Pharma	ICICI Direct	2232.30	2270.00	1911.80 (16.76%)	Target met	Buy	pdf post cache		Broker Report Gland Pharma ICICI Direct About the stock: Gland Pharma is one of the largest generic injectable-focused Along with its partners, Gland owns 1,748 products registrations globally of which ~490 in US, Europe, Canada, Australia, and New Zealand, ~73 in... pdf Copy Link Share on Share on Share on Share on Alert
	04 Nov 2025	Gland Pharma	Motilal Oswal Target	2232.30	2310.00	1911.80 (16.76%)	Target met	Buy	pdf post cache		Broker Report In-line revenue; margin miss transient Motilal Oswal Gland Pharma (GLAND) delivered in-line revenue in 2QFY26. However, EBITDA/PAT came in below our expectations by 9%/11%. A lowerthan-expected share of milestone income and lower tech transfer/CMO business in ROW markets impacted 2QFY26 performance. pdf Copy Link Share on Share on Share on Share on Alert
	04 Nov 2025	Gland Pharma	Axis Direct Target	2232.30	2170.00	1911.80 (16.76%)	Target met	Hold	pdf post cache		Broker Report Result Update:Gland Pharma Axis Direct We revise our rating from HOLD to BUY pdf Copy Link Share on Share on Share on Share on Alert
	06 Aug 2025	Gland Pharma	Axis Direct Target	2232.30	1950.00	1964.70 (13.62%)	Target met	Hold	pdf post cache		Broker Report Result Update:Gland Pharma Axis Direct We maintain our HOLD rating on the stock with a target price of Rs 1,950/share. pdf Copy Link Share on Share on Share on Share on Alert
	06 Aug 2025	Gland Pharma	Motilal Oswal Target	2232.30	2340.00	1957.50 (14.04%)	Target met	Buy	pdf post cache		Broker Report Strong margin gain boosts PAT by 50% YoY Motilal Oswal Gland Pharma (GLAND) posted revenue in line with our estimate in 1QFY26. However, EBITDA/PAT exceeded our estimates (13%/16% beat). pdf Copy Link Share on Share on Share on Share on Alert
	04 Feb 2025	Gland Pharma	Axis Direct Target	2232.30	1580.00	1458.55 (53.05%)	Target met	Hold	pdf post cache		Broker Report Result Update:Gland Pharma Axis Direct We maintain our HOLD rating with a target price of Rs 1,580, implying an upside potential of 4%, valuing the company at a PE of 20x for FY27. pdf Copy Link Share on Share on Share on Share on Alert
	03 Feb 2025	Gland Pharma	Motilal Oswal Target	2232.30	1840.00	1513.95 (47.45%)	Target met	Buy	pdf post cache		Broker Report New launches and higher milestone income drive margins Motilal Oswal Gland Pharma (Gland) delivered a better-than-expected operating performance for the quarter. While revenue came in line, product mix and a higher share of milestone income led to better-than-expected margins in the base business. pdf Copy Link Share on Share on Share on Share on Alert
	05 Nov 2024	Gland Pharma	Axis Direct Target	2232.30	1760.00	1832.85 (21.79%)	Target met	Hold	pdf post cache		Broker Report Result Update:Gland Pharma Axis Direct we maintain our HOLD rating with a target price of 1,760, implying an upside potential of ~9.4%, valuing the company at a PE of 26x for FY26. pdf Copy Link Share on Share on Share on Share on Alert
	07 Aug 2024	Gland Pharma	Axis Direct Target	2232.30	2000.00	2027.90 (10.08%)	Target met	Hold	pdf post cache		Broker Report Result Update:Gland Pharma Axis Direct We have Hold on the stock pdf Copy Link Share on Share on Share on Share on Alert
	06 Aug 2024	Gland Pharma	Motilal Oswal Target	2232.30	2440.00	2106.95 (5.95%)		Buy	pdf post cache		Broker Report Lower milestone income and ROW sales hurt earnings Motilal Oswal Gland Pharma (GLAND) reported a miss on its 1QFY25 earnings, largely due to lower milestone income for the quarter. Further, postponement of the off-take of products by European customers hit 1QFY25 performance. pdf Copy Link Share on Share on Share on Share on Alert
	23 May 2024	Gland Pharma	Axis Direct Target	2232.30	1950.00	1881.85 (18.62%)	Target met	Hold	pdf post cache		Broker Report Result Update:Gland Pharma Axis Direct Investing in capacity expansion through Capex reflects the company's commitment to meeting future demand and capturing new opportunities in the market. We have Hold on the stock pdf Copy Link Share on Share on Share on Share on Alert
	15 Feb 2024	Gland Pharma	Axis Direct Target	2232.30	1825.00	1897.10 (17.67%)	Target met	Hold	pdf post cache		Broker Report Result Update:Gland Pharma Axis Direct China remains a key geographic focus area for the company. Gland has received and launched one product this year. Recommendation: HOLD pdf Copy Link Share on Share on Share on Share on Alert
	08 Nov 2023	Gland Pharma	Axis Direct Target	2232.30	1700.00	1653.15 (35.03%)	Target met	Hold	pdf post cache		Broker Report Result Update:Gland Pharma Axis Direct Stability in the Base Business; Maintain HOLD pdf Copy Link Share on Share on Share on Share on Alert
	06 Nov 2023	Gland Pharma	Motilal Oswal Target	2232.30	1920.00	1574.85 (41.75%)	Target met	Buy	pdf post cache		Broker Report Slowly getting back on track Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	09 Aug 2023	Gland Pharma	Axis Direct Target	2232.30	1620.00	1671.65 (33.54%)	Target met	Hold	pdf post cache		Broker Report Result Update:Gland Pharma Axis Direct Injectable companies (HIKMA, HOSIPORA, and Aurobindo) in the US market reported sales growth of ~4% YoY. We expect similar growth for GLAND in the core markets over a longer period and high single-digit growth in India and RoW over a long-term. pdf Copy Link Share on Share on Share on Share on Alert
	07 Aug 2023	Gland Pharma	Motilal Oswal Target	2232.30	1560.00	1342.55 (66.27%)	Target met	Buy	pdf post cache		Broker Report Healthy recovery in core markets Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners